News

 February 1, 2000, Jerusalem, Israel. Teva Pharmaceutical Industries Ltd, (NASDAQ: TEVA) announced today that it had signed a definitive agreement to acquire 100% of Novopharm Ltd. from Dan Family Holdings Ltd. (the "Dan Family"). The execution of the definitive agreement follows our prior releases of October 19, 1999 and December 2, 1999 relating to the possibility of such a transaction. Upon the consummation of the transaction, the Dan Family will be entitled to receive approximately 4.2 million Teva Ordinary Shares, representing approximately 6% of Teva's outstanding share capital Read More »

 Jerusalem, Israel, February 14, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported financial results for the fourth quarter and year ended December 31, 1999. Total consolidated sales in the 1999 fourth quarter amounted to $379.9 million, an increase of 28% over the comparable 1998 quarter. Net income amounted to $40.1 million, compared with $1.4 million in the comparative period, the latter after absorbing one-time charges of $28.2 million. Before one time charges, 1999 net income rose 35%. Earnings per ADR for the fourth quarter of 1999 were $0.64, as compared with $0.0 Read More »

Jerusalem, Israel, February 14, 2000 - . Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that Teva's Board of Directors approved the fourth quarter dividend amounting to approximately $6.8 million, (based on current exchange rates), which reflects a 57% increase and equals approximately $0.11 per pre-split ADR. The shareholder record date for the cash dividend is February 21, 2000, and will be payable on March 15, 2000. The expected rate of income tax to be withheld at source is 25%. In addition, Teva's Board of Directors has approved a two for one stock split of the Company Read More »

Jerusalem, Israel, February 22, 2000 - Teva Pharmaceutical Industries Ltd, (NASDAQ: TEVA) announced that it will immediately launch Diclofenac Extended Release (once-a-day) in its 100 mg dosage form. Diclofenac Extended Release is the generic equivalent of Novartis Voltaren XR, which is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Branded sales of Voltaren XR in the United States for the twelve months ended December 31st, 1999 were $98 million. On February 17, 2000 Biovail Corporation International (NYSE: TSE: BVF) received the first final approval from the FDA for t Read More »

Jerusalem, Israel, March 30, 2000 - Teva Pharmaceutical Industries Ltd, (Nasdaq: TEVA) announced today that it will market exclusively in the U.S. Bio-Technology General Corp.'s (Nasdaq: BTGC) recombinant human growth hormone (hGH).Human growth hormone represents the first product to come out of the strategic alliance, which Teva entered into with Bio-Technology General in September 1999. Teva plans to launch hGH in the United States in 2000. However, the launch date could potentially be delayed pending the outcome of appellate litigation between Bio-Technology General and Genentech.Teva's Pre Read More »

Jerusalem, Israel, April 5, 2000 - Teva Pharmaceutical Industries Ltd, (Nasdaq: TEVA) announced today that it has completed the previously announced acquisition of Novopharm Ltd. Novopharm is the second largest generic drug company in Canada and has substantial operations in the United States and Hungary. Under the terms of the transactions, and as previously disclosed, Dan Family Holdings, the sole shareholder of Novopharm received equity securities representing approximately 6.2% of Teva's outstanding shares. Initially, approximately 6.2 million of such securities will be in the form of exch Read More »

JERUSALEM, Israel, April 7, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and H. Lundbeck A/S (CSE: LUN.CO) are pleased to announce the positive results of the phase III clinical trial with rasagiline in Parkinson's disease. The results of this mono-therapy study demonstrate highly significant efficacy in the primary endpoint on progression of parkinsonian symptoms. In addition, rasagiline, a selective irreversible MAO-B inhibitor, was well tolerated in this patient population.This study, which focused on early stage patients not yet treated with levodopa, was conducted in the US a Read More »

Jerusalem, Israel, April 26, 2000 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced that it had received from the US Food and Drug Administration an approval to manufacture and market Ketoconazole 2% Cream. Teva USA will launch the product immediately.Ketoconazole 2% Cream is Teva's generic version of Janssen's anti-fungal drug Nizoral® 2% Cream, of which annual US sales are approximately $65 million.Teva views this approval as significant as it is the first approval for a generic version of this drug. Unlike most oral dosage forms, this product required a 325 patient, 18 cen Read More »

Balance Sheet DataConsolidated Statements of IncomeJerusalem, Israel, May 4, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported that net income for the quarter ended March 31, 2000, reached $37.9 million compared with $28.3 million reported in the first quarter of 1999 (up 34%) and earnings per ADR were $0.30 (up 30%). Total sales for the first quarter of 2000 rose 17% to $337.3 million.Eli Hurvitz, President and Chief Executive Officer, commented: "We are pleased with the first quarter results which developed at the planned pace and reflect the impact of the various Read More »

Jerusalem, Israel, May 31, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received from the US FDA final approval to manufacture and market Nabumetone 500 mg Tablets. Nabumetone is the generic version of the SmithKline Beecham drug Relafen® for the treatment of acute and chronic osteoarthritis and rheumatoid arthritis. 1999 US sales of the branded product were approximately $220 million. As the first to file a Paragraph IV certification with respect to this product under the Waxman-Hatch Act, Teva will have 180 days of market exclusivity. A patent infring Read More »